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Abstract
Background: There is renewed interest in the development of poxvirus vector-based HIV vaccines due to the
protective effect observed with repeated recombinant canarypox priming with gp120 boosting in the recent Thai
placebo-controlled trial. This study sought to investigate whether a heterologous prime-boost-boost vaccine
regimen in Chinese cynomolgus macaques with a DNA vaccine and recombinant poxviral vectors expressing HIV
virus-like particles bearing envelopes derived from the most prevalent clades circulating in sub-Saharan Africa,
focused the antibody response to shared neutralising epitopes.
Methods: Three Chinese cynomolgus macaques were immunised via intramuscular injections using a regimen
composed of a prime with two DNA vaccines expressing clade A Env/clade B Gag followed by boosting with
recombinant fowlpox virus expressing HIV-1 clade D Gag, Env and cholera toxin B subunit followed by the final
boost with recombinant modified vaccinia virus Ankara expressing HIV-1 clade C Env, Gag and human
complement protein C3d. We measured the macaque serum antibody responses by ELISA, enumerated T cell
responses by IFN-g ELISpot and assessed seroneutralisation of HIV-1 using the TZM-bl b-galactosidase assay with
primary isolates of HIV-1.
Results: This study shows that large and complex synthetic DNA sequences can be successfully cloned in a single
step into two poxvirus vectors: MVA and FPV and the recombinant poxviruses could be grown to high titres. The
vaccine candidates showed appropriate expression of recombinant proteins with the formation of authentic HIV
virus-like particles seen on transmission electron microscopy. In addition the b12 epitope was shown to be held in
common by the vaccine candidates using confocal immunofluorescent microscopy. The vaccine candidates were
safely administered to Chinese cynomolgus macaques which elicited modest T cell responses at the end of the
study but only one out of the three macaques elicited an HIV-specific antibody response. However, the antibodies
did not neutralise primary isolates of HIV-1 or the V3-sensitive isolate SF162 using the TZM-bl b-galactosidase assay.
Conclusions: MVA and FP9 are ideal replication-deficient viral vectors for HIV-1 vaccines due to their excellent
safety profile for use in humans. This study shows this novel prime-boost-boost regimen was poorly immunogenic
in Chinese cynomolgus macaques.
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Background
The development of a safe, affordable and effective HIV-
1 vaccine remains a priority especially in sub-Saharan
Africa where the hypervariability of the virus poses the
greatest challenge. While numerous HIV-1 vaccine can-
didates have been developed, only three HIV-1 vaccine
regimens have been tested in Phase III clinical trials for
efficacy: VaxGen’s AIDSVAX gp120 vaccine induced
non-neutralising antibodies which failed to provide pro-
tection to immunised individuals [1]; the STEP vaccine
regimen comprised 3 recombinant adenovirus serotype
5 viruses expressing HIV-1 Gag, Pol and Nef, that
induced CD8+ T cell responses to viral antigens but
afforded no protection to vaccinees [2,3]; and the recent
Thai placebo-controlled trial of repeated recombinant
canarypox virus priming with recombinant gp120 boosts
was designed to give antibody rather than T cell
responses. A post-hoc modified analysis showed modest
efficacy in preventing HIV-1 infections [4], but the pla-
cebo arm did not incorporate a poxvirus control to
allow for the effects of repetitive stimulation on innate
immunity, and no antibody responses capable of neutra-
lising primary isolates of HIV-1 were demonstrated.
Modified vaccinia virus Ankara (MVA) and attenuated
fowlpox virus (FPV, particularly strain FP9) are pox-
viruses that have been safely administered to humans
[5-7] as they are replication-defective in human cells
[8,9]. In addition, the vectors have no apparent restric-
tion in the quantity of additional recombinant DNA
they can accommodate and can be grown to high titres
in chick embryo fibroblasts (CEFs). Moreover, the
recombinant poxvirus vaccine stocks are stable at room
temperatures for extended periods of time without sig-
nificant losses in titre and indefinitely if the poxvirus is
immobilised onto carbohydrate glass [10]. Recombinant
MVA (rMVA) and recombinant FPV (rFPV) have been
developed as HIV-1 vaccine candidates and tested in
heterologous prime-boost combinations with DNA vac-
cines in mice [11-13], macaques [14-18] and humans
[19-24]. These vaccine approaches principally elicit cyto-
toxic T lymphocyte (CTL) responses which are thought
to be an important component of protective immunity
to HIV-1 (reviewed in [25]). In the original prime-boost
CTL work it was found that T cell responses were selec-
tively boosted to epitopes held in common by the prim-
ing and boosting agents [26,27]. The mechanism of the
boosting is thought to be due to type-1 interferon pro-
duction stimulated by MVA (MVA lacks the soluble
interferon receptors that might block this): i.e. the adap-
tive immune response is being boosted by the innate
immune response [8]. An important limitation of T cell-
based vaccines is that they may not achieve sterilising
immunity to HIV-1, but instead will hopefully control
virus replication [28], so there has been a considerable
focus on the development of immunogens that can elicit
both T cell immunity and a broadly-reactive neutralising
antibody (NAbs) response to HIV-1 [29-31]. However,
the design immunogens that elicit NAbs that neutralise
a broad range of primary isolates is proving to be parti-
cularly challenging [32]. Nevertheless, NAbs have been
identified in chronically infected individuals that have
potent neutralising activity and monoclonal antibodies
(MAbs) have been generated from these donors
(reviewed in [32,33]. The epitopes targeted by these
antibodies have been characterised and serve as tem-
plates for candidate HIV-1 vaccines [34,35]. The data
from the VAXGEN and STEP studies using soluble
gp120 and vectored Env immunogens showed the anti-
bodies elicited were reactive with only a small subset of
V3-sensitive isolates of HIV-1 [1-3]. Thus, the design of
improved Env immunogens remains a major goal to
HIV-1 vaccinologists.
The best protection in non-human primates (NHPs) is
obtained by prior exposure to attenuated lentiviruses
where the immune correlates of protection remain ill-
defined [36] reviewed in [37]. Currently, a live attenu-
ated HIV-1 vaccine for humans is beset by safety con-
cerns due to the risks associated with mutation and
reversion to a wild-type virulent form [38]. A safe and
promising approach is to generate HIV virus-like parti-
cles (VLPs) bearing authentic Env trimers, which are a
highly effective form of subunit vaccine that mimic the
antigenic structure and size of a virus particle but lack
genetic material so are non-infectious (reviewed in [39].
VLPs are often highly immunogenic and thus there has
been considerable interest in using this approach so a
number of VLP forming HIV vaccine candidates have
been described [14,40-48] with some of the vaccines
progressing to clinical trials [20]. Some of these studies
employed a heterologous DNA prime, recombinant
rMVA boost [14,20,40,43,44,47]. However, the antibo-
dies elicited are often focused on non-functional forms
of Env, possibly gp120/41 monomers and not on func-
tional Env trimers [41] so there is a need to ensure that
the B cells are recognising functional forms of Env. In
addition, vaccine candidates will need to provide potent
immunostimulatory signals to the relevant B cells so
that high titres of NAbs are obtained. Another advan-
tage of recombinant VLP forming vaccine candidates is
that they can express additional proteins such as immu-
nostimulatory proteins to potentiate NAbs.
Adjuvants are increasingly incorporated into the
design of vaccines to further improve their immunogeni-
city (reviewed in [49,50]). The co-administration of
adjuvants necessitates continuous refrigeration, so coen-
coding adjuvants bypasses this need and simplifies
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vaccine administration in resource-limited settings. In
this study we sought to overcome the poor immuno-
genicity of cross-clade neutralising epitopes and the gen-
erally poor antibody responses of DNA prime, poxvirus
boost regimens by the incorporation of the B cell adju-
vant human complement protein C3d (hC3d) [51,52] in
the rMVA vaccine candidate and the mucosal adjuvant
non-toxic cholera toxin B (CTB) in the rFPV vaccine
candidate. The adjuvants effects of murine C3d have
been shown to boost antibody responses in mice when
coexpressed with DNA vaccines expressing Env [53-55].
Cholera toxin has been widely used an adjuvant
(reviewed in [56], and has been shown to enhance anti-
body responses when co-administered with recombinant
vaccinia [57] and MVA [58]. In this investigation, only
the B subunit was used because of the toxicity asso-
ciated with the use of the cholera holotoxin, and
because the related E.coli holotoxin has been linked
with facial palsy when co-administered with influenza
VLPs [59].
In this study, a novel prime-boost-boost vaccination
regimen was assessed for immunogenicity following vac-
cination of Chinese cynomolgus macaques. Each vaccine
vector expressed a different clade of Env (clades A, D
and C). HIV VLPs were used to deliver the Env to the
immune system as authentic Env trimers. To further
enhance the immunogenicity of Env we have coencoded
B cell adjuvants into the recombinant poxviral vectors.
We proceeded directly to a NHP model of immunogeni-
city because this model most closely resembles the likely
immune response in humans and given the fact that
certain neutralising monoclonal antibodies are known to
be polyreactive to self antigens [60,61] this avoids false
positive results from murine studies. Furthermore, the
effectiveness of hC3d is most likely to be demonstrated
in a NHP model.
Results
DNA vaccine
DNA plasmid encoding consensus HIV clade A env was
shown to express gp120 by immunofluorescence studies
on transfected HEK293 cells (Figure 1A). DNA plasmid
encoding HIV clade B gag was shown to express Gag
protein by immunofluorescence studies on transfected
HEK293 cells (Figure 1C), as previously reported [62].
In all cases specific MAbs were used with appropriate
lipofectin only controls (Figure 1B and 1D).
Recombinant poxvirus HIV vaccines
The rFPV infected CEFs were shown to express HIV Env
(Figure 1E), HIV Gag (Figure 1G) and CTB (Figure 1M)
by immunofluorescence. In addition, CEFs infected
with rMVA were shown to express gp120 (Figure 1I),
Gag (Figure 1K) and hC3d (Figure 1O) using
immunofluorescence. In all cases specific MAbs
were used with appropriate non-recombinant controls
(Figure 1).
HIV-1 neutralising epitopes
The b12 neutralising epitope was demonstrated to be
present on the surface of transfected/infected HEK293
cells for all 3 vaccine candidates using confocal immu-
nofluorescent microscopy (Figure 2), with strongest
staining for b12 seen for rMVA infected cells (Figure
2E), with less so for rFPV infected (Figure 2C) and
DNA transfected cells (Figure 2A). In all cases MAb b12
was used with appropriate non-recombinant/lipofectin
only controls (Figure 2B, D and 2F). Anti-gp120 MAb
2G12 and anti-gp41 MAb 2F5 were shown to not bind
to all recombinant infected/transfected cells under the
assay conditions employed (data not shown).
VLP formation
All three vaccine candidates were shown to produce
HIV virus-like particles on TEM of transfected/infected
human-derived HEK293 cells (Figure 3 and Additional
File 1, Figure S1). HIV VLP production was prolific in
the case of rMVA (Figure 3C and Additional File 1, Fig-
ure S1C), but much less for rFPV (Figure 3B and Addi-
tional File 1, Figure S1B). The dual DNA vaccine
produced large numbers of VLPs (Figure 3A and Addi-
tional File 1, Figure S1A) from transfected cells but the
efficiency of transfection limited the number of VLP
producing HEK293 cells. No VLPs were seen on inspec-
tion of non-transfected or uninfected HEK293 cells
(data not shown), indicating that VLP production seen
with vaccine candidates was specific.
Immunisation studies
All three animals were vaccinated simultaneously follow-
ing an identical schedule using the same batches of vac-
cine candidates. No adverse events were reported on
vaccination of macaques.
Immunogenicity studies
We first assessed HIV-specific antibody responses eli-
cited by the cynomolgus macaques following the prime-
boost-boost vaccinations by ELISA using inactivated
HIV-1 virions (clades A, D, C and B) as the antigen.
Serum antibodies were measured over the complete
time course of the study (t = 0, 2, 4, 6 and 9 weeks).
The immunisation regimen elicited HIV-specific antibo-
dies in macaque 1057 (Figure 4). The antibody response
peaked at week 6 which was 2 weeks after the macaques
had been vaccinated with the rMVA vaccine candidate
but the antibody responses were short lived as it was
much lower by week 9. The highest antibody responses
were generated to primary isolates of HIV clades D and
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C (Figure 4B and 4C). No anti-HIV antibodies were
detected in macaques 9035 and 2027.
We next assessed the magnitude of T cell responses eli-
cited in the immunised macaques against overlapping
peptide pools from either HIV-1 Gag (p24/p17) or Env
gp120 in the ex vivo IFN-g ELISpot assay (for amino acid
sequences see Additional File 2, Table S1). Macaque
1057 showed a moderate naive PBMC response to Env
peptides. All macaques elicited a positive PBMC response
to Env peptides at the end of the time course (Figure 5A).
Small preimmunised PBMC responses to Gag peptides
were detectable in macaques 1057 and 9035. All maca-
ques elicited a positive PBMC response to Gag peptides
at week 9 (Figure 5B). Splenocyte responses were clearly
seen in response to peptides from both Env and Gag in
macaque 1057 (Figure 5C and 5D). Macaques 2027 and
9035 elicited a similar splenocyte response to Gag and
Env peptides to the naïve macaque 453A (Figure 5C and
5D). Positive T cells responses from both axillary
and inguinal lymph nodes were observed in all macaques
but the strongest T cell responses were found in macaque
1057 (Figure 5E and 5F).
We next assessed whether the HIV-specific antibody
response detected in macaque 1057 would neutralise
primary isolates of HIV-1 using the TZM-bl cell
neutralisation assay. The assay was validated by the
detection of potent neutralisation of SF162 by IgG1b12
(Figure 6A), yielding similar concentrations to those
previously reported to achieve 90% and 50% neutralisa-
tion of SF162 [63]. Furthermore, there was neutralisa-
tion of a clade B primary isolate of HIV-1 (91/US/005)
by IgG1b12 (Figure 6B) and a clade C primary isolate of
HIV-1 (97/ZA/003) using the gp41 MAb 4E10 (see
Additional File 3, Figure S2). The neutralising activity of
serum from macaque 1057 was tested at baseline, week
6 and week 9. We report here that no neutralising anti-
bodies were detectable in the serum of macaque 1057 at
any of the time points through the time course of the
study. Representative HIV neutralisation assays obtained
from macaque 1057 are shown (Figure 6). There was no
HIV neutralisation when serum from macaque 1057 was
cultured in the presence of primary HIV clade A isolate
92/UG/037 (Figure 6C), clade D isolate 94/UG/114 (Fig-
ure 6D), clade C isolate 97/ZA/003 (Figure 6E) and the
b12 sensitive strain SF162 (Figure 6F). Furthermore,
there was no detectable neutralisation of 97/ZA/003
when the macaque serum was mixed with human com-
plement (Figure 6G and 6H). We also looked for NAbs
in the sera of macaques with no apparent humoral
immune response, but as expected these were negative.
Figure 1 Detection of recombinant HIV-1 proteins and adjuvants using immunofluorescent microscopy. HEK293 cells stained with: (A)
anti-gp120 post-tranfection with DNA vaccine; (B) anti-gp120 with lipofectin control; (C) anti-Gag post-transfection with DNA vaccine; (D) anti-
Gag with lipofectin control. Chick embryo fibroblasts stained with: (E) anti-gp120 post-infection with rFPV; (F) anti-gp120 post-infection with wild-
type FPV; (G) anti-Gag post-infection with rFPV; (H) anti-Gag post-infection with FPV; (I) anti-gp120 post-infection with rMVA; (J) anti-gp120 post-
infection with wild-type MVA; (K) anti-Gag post-infection with rMVA; (L) anti-Gag post-infection with wild-type MVA; (M) anti-CTB post-infection
with rFPV; (N) anti-CTB post-infection with wild-type FPV; (O) anti-hC3d post-infection with rMVA and (P) anti-hC3d post-infection with wild-type
MVA. Magnification ×50.
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Discussion
This study shows that large and complex synthetic DNA
sequences can be successfully cloned in a single step
into two poxvirus vectors: MVA and FPV and recombi-
nant poxviruses could be grown to high titres without
the recombinants reverting to their wild-type form. The
vaccine candidates showed appropriate expression of
recombinant proteins in infected/transfected cells and
the b12 epitope (coincident with the CD4 binding site
(CD4bs) of gp120) was shown to be held in common by
the vaccine candidates. The CD4bs is an important tar-
get for NAb responses identified in HIV-1 infected
individuals [64]. In addition human cells infected/trans-
fected with the vectors showed expression of authentic
HIV-like VLPs. The HIV vaccine candidates were deliv-
ered by intramuscular injection of Chinese cynomolgus
macaques in a prime-boost-boost vaccination protocol.
The vaccines were tolerated without any adverse reac-
tions. The vaccines elicited modest T cell responses in
the immunised macaques but only macaque 1057
produced an HIV-specific antibody response which was
highest after the third heterologous immunisation. How-
ever, the antibodies did not neutralise the panel of pri-
mary HIV isolates or the laboratory adapted, b12-
sensitive isolate SF162 using the TZM-bl b-galactosidase
assay. The TZM-bl neutralising antibody readout has
been validated against protection from SHIV infection
in passive transfer experiments [65]. Our immunisation
protocol was shorter than those generally used for subu-
nit vaccines aimed at eliciting antibody responses but in
keeping with those used for heterologous prime-boost
aimed at eliciting T cell responses. Antibody responses
capable of neutralising SHIV are generally apparent
after the second subunit boost [66], but in natural HIV
infection it can take some time to emerge [67-69]. We
detected no evidence of NAb responses 5 weeks after
the third heterologous immunisation.
The vaccine candidates directed VLP secretion from
infected/transfected cells in vitro, however, we have not
demonstrated VLP production following vaccination in
vivo: a difficult subject to study without biopsying vacci-
nation sites. The rMVA produced a prolific number of
VLPs from infected HEK293 cells compared to the
DNA and rFPV vaccines. Recombinant proteins in MVA
were expressed from combination early/late promoters
(both being effective in mammalian cells) whereas the
recombinant proteins in FPV were expressed from early
promoters alone (only early promoters being effective in
FPV-infected mammalian cells). We have not proved
that Env is incorporated in the membranes of the VLPs,
although the appearance of Env spikes on TEM is highly
suggestive. Others have also reported expression of the
b12 epitope on Gag-Env pseudovirions [70] but not in
the context of carriage by poxviruses. Expression and
VLP formation from the plasmid constructs used in the
DNA vaccine would probably have been enhanced if a
single plasmid expressing both Env and Gag were used,
but we were unable to obtain such materials. The Env
expression plasmid employed is rev-independent. We
used codon-optimised env consensus sequences for
clades A and C which are known to be functional and
CCR5-using. No consensus sequence for clade D env
was available at the time, so we derived a codon-opti-
mised version from the CCR5-using infectious molecular
clone U88824. Functional consensus sequences were
used where possible because these are believed to
enhance NAb responses [71].
The reason for the failure to generate NAbs is not
clear. It may be that the vectors employed simply do
not generate good antibody responses despite the
attempts to improve this with hC3d and CTB. The
hC3d was incorporated towards the N-terminus of Env
(essential if it is to be displayed on the external surface
of a VLP) whereas the original work in rodents with hen
Figure 2 Detection of a b12 epitope expressed by HIV-1
vaccine candidates. Staining of HEK293 cells with IgG1b12 post-
transfection/infection with HIV vaccine candidates: (A) post-
transfection with clade A Env expressing DNA vaccine; (B) lipofectin
control; (C) post-infection with rFPV; (D) post-infection with wild-
type FPV; (E) post-infection with rMVA; (F) post-infection with wild-
type MVA. Magnification ×200.
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egg lysozyme emphasised the importance of incorpora-
tion at the C terminus [51]. Furthermore, most reports
describe the use of murine C3d as molecular adjuvants
[51,72] but here we used hC3d because we reasoned it
was more relevant for human vaccine development and
our NHP model. In addition, we have not used triplet
sequences of hC3d because highly repetitive sequences
are rapidly deleted by poxviruses, and we predicted the
trimeric structure of HIV Env would perform this func-
tion naturally anyway. The approach of using C3d as a
molecular adjuvant in recombinant viral vectors has
recently been shown to hamper antibody responses to
certain antigens [73] and this study suggests that encod-
ing C3d was counterproductive to the vector design.
CTB was preferentially expressed in FPV not MVA,
because MVA is known to block the effect of interleu-
kin-1b [8] by production of a soluble receptor, and this
would likely interfere with the adjuvant effect of CTB
[74]. Furthermore, the CTB was designed to be secreted
from poxvirus-infected cells with no fusion with candi-
date HIV antigens. We have not proved that the CTB
and hC3d expressed by the poxviruses are functional.
Since these experiments were conceived it has also
become apparent that the native b12 epitope is a poor
immunogen: it is located deep in the CD4bs, so the b12
MAb has an unusually extended variable loop in order
to bind the epitope. Studies suggest that steric
hindrance, e.g. by beta20-beta21 loop [75], would pre-
vent good immune responses to this epitope in a similar
fashion to steric hindrance of any coreceptor binding
site epitopes [76]. Furthermore, naturally glycosylated
HIV-1 Env trimers are poor immunogens, so it is possi-
ble that further modifications to the Env amino acid
sequence in order to better expose neutralising epitopes
might be beneficial in addition to the cross-clade immu-
nisation employed here.
Although we have focused on the b12 epitope it is
quite possible that there were other cross-clade neutra-
lising epitopes present in the vaccine candidates,
whether on gp120 or gp41. For example, the highly con-
served caveolin-binding motif (623WNNMTWMEW631)
of gp41 is represented in the amino acid sequence of all
the constructs [77,78], although this does not appear to
be immunogenic except when expressed in isolation.
The TZM-bl b-galactosidase assay we employed would
be expected to detect the effect of any antibody such as
the gp120 MAb IgG1b12 that interfered with HIV-CD4
binding, HIV-coreceptor binding or fusion of HIV Env
and target cell membrane. It is known that certain anti-
body subpopulations such as 2G12-like antibodies, may
not be detected through the use of the TZM-bl assay
[79] and that high levels of CCR5 expression can reduce
sensitivity for antibodies such as 4E10 [80]. Even so, this
assay is the most standardised and widely applied assay
Figure 3 HIV VLP secretion by HEK293 cells infected/transfected with vaccine candidates as revealed by TEM: (A) post-transfection
with dual plasmid DNA vaccine candidate. Magnification × 100,000; (B) post-infection with rFPV. Magnification × 100,000; (C) post-infection
with rMVA. Magnification × 100,000. Uninfected HEK293 cells were screened by TEM for virus particles but no viruses were observed in any grids
(data not shown). Bar = 120 nm.
Bridge et al. Virology Journal 2011, 8:429
http://www.virologyj.com/content/8/1/429
Page 6 of 15
for the measurement of neutralising antibodies
[65,80,81] and alternative formats such as PBMC-based
assays show great variability in sensitivity in inter-
laboratory comparisons [80].
T cell responses were clearly seen on ELISpots to con-
served Gag and Env peptides in the macaques at the end
of the study (five weeks after the final rMVA immunisa-
tion). This finding is consistent with previous studies in
cynomolgus macaques using DNA prime, MVA boost
regimens [82,83]. T cell responses in DNA prime, pox-
virus boost regimens generally peak earlier than this at
around 1 week post-immunisation [27], so it is possible
that more vigorous T cell responses have been missed.
It may also be the case that cross-clade T cell responses
in macaques may not translate to humans, because the
T cell epitopes are different and many are clade-specific.
Of note both antibody and T cell responses were best
in the heaviest macaque 1057, the other two macaques
were significantly smaller (see Additional File 4, Table
S2). There was no obvious pathology at post mortem in
any of the macaques. HIV and SIV vaccine candidates
have not been extensively studied in Chinese cynomol-
gus macaques, and there is no data on MHC types, so
future investigations may be better performed in the
rhesus macaque model.
In conclusion, FPV and MVA are ideal replication-
deficient viral vectors for HIV-1 vaccines due to their
excellent safety profile for use in humans. This study
shows that the DNA and poxvirus vectors used accord-
ing to the immunisation protocol were poorly immuno-
genic in Chinese cynomolgus macaques. Furthermore,
the antibodies elicited in the macaque did not neutralise
primary or lab adapted isolates of HIV-1. Clearly it is
very difficult to prove a negative result, and we cannot
exclude the possibility that the viral vectors may elicit
NAbs in combination with other vaccine candidates or
in different model systems (e.g. Rhesus macaques), or
with modifications to the vaccine vectors or adjuvants.
Figure 4 Antibody responses to HIV-1. Antibody responses from vaccinated macaque 1057 in serum samples collected at: week 0 (black line);
week 2 (green line); week 4 (mauve line); week 6 (red line) and week 9 (blue line) to primary isolates of HIV-1/SF162 as measured by ELISA.
Serum antibody responses to: (A) clade A 92/UG/037; (B) clade D 94/UG/114; (C) clade C 97/ZA/003; (D) SF162. Determinations were duplicated
and represented as the mean of 2 tests ± SEM.
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The level of VLP production by the MVA recombinant
was prolific, and this rMVA vaccine candidate may be
worth revisiting with DNA and FPV vaccine candidates
that are equally prolific producers of VLPs. We draw
attention to the fact that we have published comprehen-
sive sequence data and we will make our reagents avail-
able to bona fide vaccine researchers who wish to
explore these issues.
Methods
Cell lines
The HEK293 kidney cell line was obtained from the Eur-
opean Collection of Cell Cultures (ECACC, Salisbury,
UK). CEFs were obtained from 9-10 day old embryonated
eggs from specific pathogen free Rhode Island Red chick-
ens (Institute of Animal Health, Newbury, UK). Human
peripheral blood mononuclear cells (PBMCs) were
obtained as leucopaks (Merseyside Blood Transfusion
Service, Liverpool, UK) and from healthy donors. TZM-bl
cells [84,85] were obtained from the NIH AIDS Reference
and Reagent Program (NIH ARRRP; Germantown, US).
DNA vaccine
Two DNA expression vectors used for immunisation were
codon-optimised for human expression. A plasmid
(pcDNA3.1-A consensus gp160-opt) encoding HIV clade
Figure 5 HIV-specific T cell responses by IFN-g ELISpots at week 9. (A) Pre-immunised and post-immunised Env-specific peripheral blood
mononuclear cell (PBMC) responses; (B) pre-immunised and post-immunised Gag-specific PBMC responses; (C) Env-specific splenocyte responses;
(D) Gag-specific splenocyte responses; (E) Env-specific axillary and inguinal lymph node responses and (F) Gag-specific axillary and inguinal
lymph node responses. Data is duplicated and presented as the mean number of spot-forming units/106 cells ± SEM.
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A consensus gp160 (GenBank: HM070998) under a CMV
immediate early promoter was obtained from Beatrice
Hahn and the other plasmid (pHCMVwhvgagml) encod-
ing HIV clade B gag (codon-optimised for human expres-
sion) under a CMV early promoter was obtained from
Don Anson. The clade B gag sequence was derived by
Don Anson from the published sequence data for HIV-1
strain YU2 (GenBank: M93258). Plasmid DNA for
injections was purified on anion exchange columns
(Endotoxin-free Plasmid Maxi kit, QIAGEN, Crawley, UK)
and diluted in endotoxin-free saline (0.9% w/v NaCl).
Recombinant FPV vaccine
FPV strain FP9 was used. Open reading frames for full
length codon-optimised HIV-1 clade D gag, env and
CTB (fused to poxvirus leader sequence) were arranged
Figure 6 HIV-1 neutralisation assays. (A) Potency of IgG1b12 at neutralising lab-adapted isolate SF162, 1:5 IgG1b12 = 20 μg/mL; (B) potency
of IgG1b12 at neutralising primary clade B isolate 91/US/005, 1:5 b12 = 20 μg/mL; Macaque serum collected at 3 time points: Solid black line =
week 0; solid blue line = week 6; solid red line = week 9. Macaque 1057 seroneutralisation of primary isolates: (C) clade A isolate 92/UG/037; (D)
clade D isolate 94/UG/114; (E) clade C isolate 97/ZA/003; (F) lab-adapted clade B isolate SF162; (G) human complement/macaque serum and
clade C isolate 97/ZA/003; (H) heat inactivated human complement/macaque serum and clade C isolate 97/ZA/003. Data are presented as the
mean of 3 tests ± SEM.
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on a single stretch of DNA with synthetic back-to-back
early poxviral promoters driving the HIV components
(GenBank: HM070999). The HIV-1 clade D gag and env
amino acid sequence was derived directly from the
infectious molecular clone U88824. This DNA was
synthesised de novo (Blue Heron Biotechnology, Bothell,
USA); the open reading frames were not entirely codon-
optimised because some bases were changed to reduce
predicted RNA secondary structure. Certain unique
restriction sites were preserved; poxvirus termination
sequences and the ribosomal slippage site were mutated.
The synthetic sequence was flanked by NgoMIV sites,
which were used for subcloning into the XmaI (SmaI)
site of the pEFL29 recombination vector. Correct orien-
tation of the insert was necessary so that CTB subunit
production would be driven by an existing promoter in
pEFL29.
Recombinant MVA vaccine
MVA from human smallpox vaccine stock (obtained
from Anton Mayr) was used. Open reading frames for
full length consensus codon-optimised clade C gag and
env were arranged on a single stretch of DNA with syn-
thetic back-to-back early/late poxviral promoters driving
the HIV components. The sequence for monomeric
hC3d (cynomolgus macaque C3d gene sequence is not
available, rhesus macaque C3d shows 95% amino acid
sequence homology to hC3d) was inserted just after the
env leader sequence, with intervening Gly/Ser spacer
polypeptide sequence. The active site Cys codon of C3d
was mutated to Ser. The env sequence was further mod-
ified to enhance gp41/gp120 cleavage by incorporation
of six Arg residues at the furin cleavage site, and a disul-
phide bridge was introduced to link gp41 and gp120 by
mutating the Ala 480 codon and Thr 584 codon to Cys
codons. (GenBank: HM071000). This DNA was synthe-
sised de novo (Blue Heron Biotechnology); the open
reading frames were not entirely codon-optimised
because some bases were changed to reduce predicted
RNA secondary structure. Certain unique restriction
sites were preserved; poxvirus termination sequences
and the ribosomal slippage site were mutated. The syn-
thetic sequence was flanked by NgoMIV sites which
were used for subcloning into the XmaI (SmaI) site of
the pSC11 recombination vector (obtained from Geof-
frey Smith).
Verification of recombinants
Recombinant virus was isolated using b-galactosidase
substrate X-gal (5-bromo-4-chloro-3-indoyl-D-galacto-
pyranoside) soft-agar overlay of infected CEF mono-
layers (MVA, [86]; FPV, [87]). Plaque-purification was
performed six times on CEFs prior to large-scale virus
propagation and purification on sucrose cushions. Purity
and titre of poxvirus recombinants were checked by pla-
que assay on primary CEFs under soft agar with an X-
gal overlayer.
Confirmation of protein expression
Expression of recombinant proteins was demonstrated
by immunofluorescence of infected CEFs/transfected
HEK293 cells using the following MAbs: anti-gp120
(NIH ARRRP) [88]; anti-p24 (NIH ARRRP) [89]; anti-
CTB (Abcam, Cambridge, UK); and anti-human C3d
(Abcam) followed by detection with appropriate second-
ary antibodies. Expression of neutralising epitopes was
shown by confocal immunofluorescence of infected/
transfected HEK293 cells using the anti-gp120 MAb
IgG1b12 [90,91], anti-gp120 MAb 2G12 [92] and anti-
gp41 MAb 2F5 [93](NIH ARRRP) followed by detection
with appropriate secondary antibodies.
Electron microscopy of HIV VLPs
HEK293 cells were co-transfected with 2.5 μg of each
plasmid and incubated for 48 hours at 37°C with 5%
CO2. HEK293 cells were infected with recombinant pox-
virus vaccine candidates at a multiplicity of infection
(MOI) of 5 and 50 and incubated for 24-48 hours at 37°
C with 5% CO2. HEK293 cells were washed and fixed in
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer
(pH 7.3) for 1 hour. Samples were washed twice with
phosphate buffered saline (PBS) and resuspended in 2.5
mL of 50% ethanol and pelleted by centrifugation. The
cells were dehydrated in a graded ethanol series and
embedded in medium grade LR white embedding resin
(SPI, Pennsylvania, US). The resin-embedded tissues
were sectioned with an ultramicrotome, stained with 2%
uranyl acetate (pH 7) and lead citrate, and the sections
were examined using the Jeol CX100 transmission elec-
tron microscope and documented on photographic film.
Cynomolgus macaques
Three male 4-5 year old cynomolgus macaques (Macaca
fascicularis) were obtained from a Home Office
approved breeding colony in China and were acclima-
tised for two weeks prior to the study commencing. All
animals were housed according to the Code of Practice
of the UK Home Office (1989) and were sedated with
ketamine hydrochloride prior to immunisation and/or
venepuncture. All procedures involving animals were
approved by the Ethical Review Committee of the
Health Protection Agency, UK.
Immunisations
Macaques were immunised by intramuscular injection
over a time course of 9 weeks post-acclimitisation. The
DNA vaccine (0.5 mg of each plasmid in saline) was
injected into the quadriceps muscle of the left leg,
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followed by boosting 2 weeks later with rFPV vaccine (2
× 108 plaque forming units [pfu]) by injection into the
quadriceps of the right leg, followed by a further boost
2 weeks later with rMVA vaccine (2 × 108 pfu) by injec-
tion into the biceps muscle of the left arm of each
macaque. Whilst under sedation clinical parameters
were checked such as body weight, temperature and
scoring of lymph node swelling (see Additional File 4,
Table S2). Blood was collected prior to each immunisa-
tion, then at week 6 and week 9. The immunisation
sites were checked for assessment of any adverse
reactions.
ELISA for HIV-specific antibodies
Primary and laboratory-adapted isolates of HIV-1 were
quantitated using a p24 ELISA (BIORAD, Hemel Hemp-
stead, UK). Immunolon-4 microtitre plates were coated
using 500 ng/well of p24 antigen from the HIV-1 iso-
lates in 100 μL RPMI-1640. The virus was inactivated
by the addition of 100 μL of b-propiolactone (VWR,
Lutterworth, UK; diluted 1:1000 in PBS) and incubated
overnight at 4°C. The plates were incubated at 37°C for
3 hours to hydrolyse the b-propiolactone, washed and
blocked with 3% goat serum. Macaque serum was
diluted (1:5) in blocking buffer followed by serial dou-
bling dilutions in appropriate wells and incubated at 37°
C for 1 hour. The negative control was 15% foetal
bovine serum in RPMI-1640. Following a wash, 100 μL
of goat anti-macaque IgG-HRP conjugated antibody
(diluted 1:25000; AbD Serotec, Kidlington, UK) was
added to each well and incubated at 37°C for 1 hour.
Following a wash, 100 μL of tetramethylbenzidine
(Sigma, Poole, UK) was added and incubated at room
temperature in darkness for 30 minutes. The reaction
was stopped by the addition of 1N H2SO4 (Sigma).
Absorbances were read at 450 nm. Determinations of
duplicate or triplicate tests were averaged ± SEM. Posi-
tive antibody responses were defined as twice the back-
ground control.
IFN-g ELISpots
Mononuclear cells were obtained from peripheral blood
and tissue by density gradient centrifugation using stan-
dard procedures. Sterile 96-well polyvinylidene difluor-
ide multiscreen plates (Millipore, Billerica, USA) were
coated with 100 μL/well of 15 μg/mL GZ-4 coating anti-
body (MabTech, Nacka Strand, Sweden). Mononuclear
cells were plated in duplicate at either: 2 × 105 and 1 ×
105 cells/well. Following a wash, the cells were incu-
bated with medium alone or with peptide pools (Gag
and Env) (NIBSC, Potters Bar, UK). Peptides were either
15 mers or 20 mers and of conserved sequences (see
Additional file 2, Table S1) known to be present in the
vaccines. Plates were incubated at 37°C with 5% CO2 for
16 hours. Following a wash, 100 μL/well biotinylated
detector 7-B6-1 antibody (MabTech) diluted to 1 μg/mL
in PBS containing 0.5% filtered-FCS was added and
incubated at 37°C for 2 hours. Following a wash, Strep-
tavidin-alkaline phosphatase (MabTech) diluted 1:1000
with PBS containing 0.5% FCS was added at 100 μL/well
and incubated for 2 hours followed by washing. 100 μL/
well of 5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitro
Blue Tetrazolium (BCIP/NBT) substrate (Sigma) was
added and left at room temperature for 30-60 minutes
to allow the reaction to take place producing blue spots
around sites of IFN-g producing cells. After washing, the
plates were read and enumerated using an AID ELISpot
reader system (Autoimmun Diagnostika GmbH, Straß-
berg, Germany). Data was analysed by subtracting the
mean number of spots in the medium and cells-only
control wells from the mean counts of spots in wells
with antigen. T cell responses were defined as positive if
the number of spot-forming cells were at least twice
that of either the naïve macaque control or the preim-
munised control.
Viruses
Primary isolates of HIV-1 including 97/ZA/003, 94/UG/
114, 92/UG/037, US/91/005 and SF162 were obtained
from the NIH ARRRP. HIV was propagated on PBMC
isolated from leucopaks (Merseyside Blood Transfusion
Service) employing histopaque (Sigma) density separa-
tion followed by stimulation with PHA (Sigma) and IL-2
(NIH ARRRP). High titre supernatants were identified
by p24 ELISA using a HIV-1 Ag EIA kit (BIORAD).
TZM-bl b-galactosidase assay
Neutralisation assays were performed in 96 well, flat-
bottomed plates and in triplicate. Wells were seeded
with 104 TZM-bl cells and incubated for 24 hours
[84,85]. The TZM-bl cells were treated for 30 minutes
with medium containing 2 ng/mL of polybrene (Sigma)
and washed with fresh growth medium immediately
before the addition of the virus/antibody mixes. HIV
was diluted to give 100-200 blue foci per well and
mixed with various dilutions of heat inactivated maca-
que sera or IgG1b12. After incubation for 30 minutes in
round-bottom 96 well plates the virus/antibody mixes
were transferred onto the TZM-bl cells and incubated
for 36-48 hours. Monolayers were fixed briefly with a
formaldehyde/glutaraldehyde mix, washed and stained
with X-gal solution (4 mM of potassium ferrocyanide, 4
mM potassium ferricyanide, 2 mM MgCl2, 0.4 mg/mL
X-gal) for 50 minutes. Wells were washed with PBS.
Individual wells were photographed and blue foci
counted. Data are presented as the percentage of neutra-
lisation in the serum samples compared to the virus-
only control ± SEM.
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TZM-bl b-galactosidase assay with human complement
Peripheral blood was taken by venepuncture from nor-
mal healthy volunteers and incubated at room tempera-
ture until blood was fully coagulated. Serum was
collected after centrifugation. Half of the serum was
heat inactivated by incubating at 56°C for 90 minutes.
HIV isolate 97/ZA/003 was diluted to give 100-200 foci
per well. Human sera (heat inactivated or normal
serum) was mixed 1:1 with macaque serum and incu-
bated with the diluted HIV. The remaining method is
described in the section above.
Additional material
Additional file 1: Figure S1. HIV VLP secretion by HEK293 cells infected/
transfected with vaccine candidates as revealed by TEM: post-transfection
with dual plasmid DNA vaccine candidate. Magnification × 75,000 (A),
post-infection with rFPV. Magnification × 100,000 (B), post-infection with
rMVA. Magnification × 60,000 (C). Uninfected HEK293 cells were screened
by TEM for virus particles but no viruses were observed in any grids
(data not shown). Bar = 100 nm.
Additional file 2: Table S1. Amino acid sequences of the overlapping
peptide pools used in ELISpot studies.
Additional file 3: Figure S2. Shows the potency of MAb 4E10 (100 μg/
mL) at neutralising the primary clade C HIV isolate 97/ZA/003 using the
TZM-bl b-galactosidase assay. Error bars represent the mean of triplicate
tests.
Additional file 4: Table S2. Clinical parameters of the Chinese
cynomolgus macaques.
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